English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Thursday, February 20, 2025
Eisai Selected for "Human Capital Leaders 2024" and "Human Capital Management Gold Quality" for Second Consecutive Year, as a Company Committed to Excellent Management and Disclosure of Human Capital Initiatives
Friday, February 14, 2025
Development of Prediction Model for Brain Amyloid-Beta Accumulation for Early Screening of Alzheimer's Disease
Monday, February 3, 2025
Eisai to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies
Friday, April 1, 2022
Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business
エーザイ、デジタルソリューションビジネスの基盤強化と迅速な拡大をめざしたArteryexの株式取得(子会社化)に関するお知らせ
Monday, March 28, 2022
Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor
ギリアド・エーザイ・EAファーマ、JAK阻害剤「ジセレカ(R)錠」について、既存治療で効果不十分な中等症から重症の潰瘍性大腸炎の適応追加承認を取得
Tuesday, March 22, 2022
エーザイとバイオジェン、抗アミロイドβ(Aβ)プロトフィブリル抗体レカネマブに関する最新の知見を第16回アルツハイマー・パーキンソン病学会(AD/PD(TM) 2022)において発表
Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting
Wednesday, March 16, 2022
バイオジェンとエーザイはアルツハイマー病治療薬の提携契約を変更

Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575